![]()
MIRA INFORM
REPORT
|
Report Date : |
20.06.2011 |
IDENTIFICATION DETAILS
|
Name : |
BOSCH PHARMACEUTICALS (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
Plot # 221, Sector
23, Korangi Industrial Area, Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
1992 |
|
|
|
|
Com. Reg. No.: |
0027160 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Pakistan |
b2 |
b2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Bottom of Form
BOSCH PHARMACEUTICALS (PRIVATE) LIMITED
|
Registered Address
& Factory |
|
Plot # 221, Sector
23, Korangi Industrial Area, Karachi, Pakistan |
|
Tel # |
92 (21) 35053103 |
|
Fax # |
92 (21) 35053104 |
|
Email |
marketing@bosch-pharma.com |
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1992 |
|
c. |
Registration # |
0027160 |
|
Address |
8, Modern Society,
Tipu Sultan Road, Karachi, Pakistan |
|
Tel # |
92 (21) 34541876,
34541878, 34543618, 34543641 |
|
Fax # |
92 (21) 34545915 |
M/s F. Ahmad & Co.
(Chartered
Accountants)
10/4, Bank House No. 1, Habib Square, M.A. Jinnah Road, Karachi, Pakistan
Subject Company was established as a Private Limited Company in 1992
|
Authorized Capital |
Rs. 100,000,000/-
divided into 1,000,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 80,000,000/- divided into 800,000 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. S. Mohiuddin Chawla Mr. Zakaria Nasib Mr. Farhan Chawla Mr. Ahmed Nasib |
Pakistani Pakistani Pakistani Pakistani |
43/30, Block No. 7 & 8, Overseas Co-operative Housing Society, Karachi 43/30, Block No. 7 & 8, Overseas Co-operative Housing Society, Karachi 38-O, Block 6, P.E.C.H.S., Karachi 43/30, Block No. 7 & 8, Overseas Co-operative Housing Society, Karachi |
Business Business Business Business |
Chief Executive Director Director Director |
|
Names |
No. of Shares |
|
Mr. S. Mohiuddin Chawla Mr. Zakaria Nasib Mr. Farhan Chawla Mr. Ahmed Nasib |
203,750 199,700 196,250 200,300 |
A. Subsidiary
None
B. Associated
Companies
(1) Pakistan International Packages (Pvt.) Ltd, Pakistan.
(2) Munico Associates International, Pakistan.
(3) Linz Pharmaceuticals
(Pvt) Limited, Pakistan.
Manufacture & marketing of different pharmaceutical class
like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic
Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins,
Phenothiazine, Hypolipidaemics, Muscle Relaxant with their brand names of ALOC, AMKAY, AMPIN, AMPLUS, ATLIN, BEASY,
BOSCHOCLOX, BOSCHOFEN, BOSCHTAMOL, BOSCHTAN, BOSCHTRIM, BTROL, CALAMOX, CALOC,
CEBAC, CEBOSH, CEFALOR, CEFAZOL, CEFOTAX, CEFRINEX, CEFXONE, CEPRAZONE,
CHLORAMPHENICOL, CORACE, DEXAMEX, DOLO-K, DROMAX, DURIDE, FORTAZIM, GENTIC,
GLAX, IVCEF, LOREFECT, MALADRIN, NOROCIN, NULCER, NUZIB, ODENIL, OGREL, OLINC,
OMEZOL, ORTHOFENAC, ORVA, OSTEON, PEPTILOC, PRELOX, PROTOZOL, QUINOFLOX, QUMIC,
SAISTA, SOMEZOL, SUPRAMOX, TANZO, TARIFLOX FORTE, TEZOX, ULCELOC, VARIBA,
ZECEF, ZEZOT
218
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves varying processes of
manufacturing.
|
Year |
In Pak Rupees |
|
2009 |
330,000,000/- (Estimated) |
(Foreign)
· AUROBINDO PHARMA, INDIA.
· INOGENT LABORATORIES (PVT) LIMITED, INDIA.
· AURINDO PHARMA, INDIA.
Mainly exist at all major cities of Pakistan
Mainly to Afghanistan & African Countries
· United Bank Limited, Pakistan.
· MCB Bank Limited, Pakistan.
· Allied Bank Limited, Pakistan.
· Habib Bank Limited, Pakistan.
· Pakistan Pharmaceutical Manufacturers Associations.(PPMA)
·
Karachi Chamber of Commerce & Industry.(KCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 86.05 |
|
UK Pound |
1 |
Rs. 139.30 |
|
Euro |
1 |
Rs. 123.00 |
Subject Company was established in 1992 and is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation is good. Trade relations are reported as fair. Company can be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.93 |
|
UK Pound |
1 |
Rs.72.43 |
|
Euro |
1 |
Rs.63.62 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.